3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Melanoma
11
Carcinoma, Non-Small-Cell Lung
7
Pancreatic Neoplasms
5
Triple Negative Breast Neoplasms
4
Neoplasms
4
Sarcoma
3
Neoplasm Metastasis
3
Head and Neck Neoplasms
3
Lymphoma
2
Liver Neoplasms
2
Kidney Neoplasms
2
Carcinoma, Renal Cell
2
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Thyroid Carcinoma, Anaplastic
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Spinocerebellar Degenerations
1
Small Cell Lung Carcinoma
1
Skin Neoplasms
1
Recurrence
1
Prostatic Neoplasms
1
Neuroectodermal Tumors, Primitive
1
Nasopharyngeal Neoplasms
1
Nasopharyngeal Carcinoma
1
Multiple Myeloma
1
Metastatic Pancreatic Ductal Adenocarcinoma
1
Mesothelioma
1
Lymphoma, Large B-Cell, Diffuse
1
Lung Neoplasms
1
Interventions
Carboplatin
25
Bevacizumab
18
Paclitaxel
17
Pemetrexed
16
Erlotinib Hydrochloride
14
Radiotherapy
12
Docetaxel
9
Gemcitabine
7
Cisplatin
6
ceritinib
5
Taxes
5
Cetuximab
5
pembrolizumab
3
pegfilgrastim
3
capmatinib
3
Surgical Procedures, Operative
3
Radiosurgery
3
Metformin
3
Gefitinib
3
Cyclophosphamide
3
Thalidomide
2
Sorafenib
2
Radiotherapy, Conformal
2
Nivolumab
2
Immunoglobulin G
2
Filgrastim
2
Disulfides
2
Albumin-Bound Paclitaxel
2
5-(2,4-dihydroxy-5-isopropylphenyl)-4-(4-morpholin-4-ylmethylphenyl)isoxazole-3-carboxylic acid ethylamide
2
veliparib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Has results
×
Adenocarcinoma of Lung
×
spartalizumab
×
Clear all
No trials found.